Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Paclitaxel Poliglumex (CT-2103)/Carboplatin vs Paclitaxel/Carboplatin for the Treatment of Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer (NSCLC) in Women With Estradiol > 25 pg/mL

NCT00576225 is registered in ClinicalTrials.gov with CTI BioPharma as lead sponsor.

NCT NCT00576225
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00576225 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Paclitaxel Poliglumex (CT-2103)/Carboplatin vs Paclitaxel/Carboplatin for the Treatment of Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer (NSCLC) in Women With Estradiol > 25 pg/mL
Lead sponsor
CTI BioPharma
Phase
Phase 3
Overall status
Withdrawn
Start date
September 30, 2007
Completion date
April 5, 2010
Enrollment
0 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc